WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Wendy Commins Holman to its Board of Trustees. Ms. Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases.

Prior to founding Ridgeback Biotherapeutics, Ms. Holman was a principal at Ziff Brothers Investments and director of research at ZBI Equities, a multi-billion dollar public equity investment fund where she spent 15 years guiding investments in healthcare and novel technology.

“We are very pleased to welcome Wendy to our board,” said Dr. Axel Hoos, chairman of Sabin’s Board of Trustees. “Her knowledge and experience of innovative technologies and deep interest in global health will be an important addition to the board as we advance our vision of a future free from vaccine-preventable diseases.”

The addition of Ms. Holman to the Board of Trustees comes as the Sabin Vaccine Institute has implemented a strategic plan and mission to make vaccines more accessible, enable innovation and expand immunization across the globe.

“I am delighted to join Sabin at such an opportune moment for the organization,” said Ms. Holman. “I look forward to supporting Sabin’s efforts to expand immunization and explore new scientific approaches to identify solutions with the potential to improve the lives of millions of people around the world.”

“It has been my privilege over the years to work with wonderful people and be able to assess and invest in health technology,” Ms. Holman said. “Now I am focused on bringing those solutions to everyone, regardless of where they were born. By championing immunization, we can have an immediate impact on human suffering. Every mother – every human being – should care about preventing disease and providing a healthy start for every child and every family.”

In addition to her role at Ridgeback Biotherapeutics, Ms. Holman serves as the campaign chair for the University of Pennsylvania’s new Biotech Commons and on the Penn Libraries Board of Overseers. She lives in Miami, FL with her husband and four children.

Founded in 1993, Sabin delivers sustainable, evidence-based solutions that extend the benefits of immunization to everyone, everywhere. In late 2016, after a rigorous strategic planning process, Sabin’s Board of Trustees adopted a new strategic plan and identified three strategic ambitions that will guide the organization’s growth: enabling vaccine access and uptake, advancing vaccine knowledge and innovation, and researching and developing new vaccines. Sabin is currently evaluating new research and development opportunities, seeking projects with transformative potential to improve lives through immunization.


About The Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit sabin.org and follow us on Twitter, @SabinVaccine.

Media Contact
Hannah Bassett
+1 202 621 1691